Pressrelease
Umea, Jan 29, 2009
Betagenon announces that its lead AMPK activator drug candidate BG8702 has started IMP enabling studies in the UK.
.
|
Pressrelease Umea, Jan 29, 2009 Betagenon announces that its lead AMPK activator drug candidate BG8702 has started IMP enabling studies in the UK. .
|